Pfizer Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.95 Est; Raises FY2026 Sales Guidance from $59.500B-$62.500B to $60.500B-$62.500B vs $61.793B Est

Benzinga Newsdesk www.benzinga.com Negative 47.3%

Neg 47.3% Neu 0% Pos 0%

Pfizer (NYSE:PFE) affirms FY2026 Adj EPS guidance from $2.80-$3.00 to $2.80-$3.00 vs $2.95 analyst estimate. Raises FY2026 sales outlook from $59.500 billion-$62.500 billion to $60.500 billion-$62.500 billion vs $61.793 billion estimate.